Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
Hageman SHJ, Dorresteijn JAN, Bots ML, Asselbergs FW, Westerink J, van der Meulen MP, Mosterd A, Visseren FLJ; UCC-SMART Study Group; Asselbergs FW, Nathoe HM, de Borst GJ, Bots ML, Geerlings MI, Emmelot MH, de Jong PA, Leiner T, Lely AT, van der Kaaij NP, Kappelle LJ, Ruigrok YM, Verhaar MC, Visseren FLJ, Westerink J.
Hageman SHJ, et al. Among authors: bots ml.
Eur J Prev Cardiol. 2022 Mar 30;29(4):635-644. doi: 10.1093/eurjpc/zwab028.
Eur J Prev Cardiol. 2022.
PMID: 34009323